Lessons from a French collaborative case–control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy

Table 3 Characteristics of the cases during the year after A/H1N1 2009 pandemic influenza according to age

	n	Cases <18 years (n = 33)	n	Cases ≥18 years (n = 11)	p
Change in FEV₁, %, mean (SD)^a
Month 1	33	8.8 (18.0)	11	4.5 (16.92)	0.66
Month 3	33	0.8 (8.3)	6	0.5 (5.2)	0.97
Month 12	33	−1.5 (11.0)	9	3.9 (13.6)	0.26
Change in FVC, %, mean (SD)^a
Month 1	33	5.4 (15.3)	11	4.3 (12.2)	0.88
Month 3	33	0.9 (8.1)	11	−0.8 (5.4)	0.60
Month 12	33	−0.6 (10.9)	11	6.4 (13.9)	0.11
Antibiotics, number of treatments, mean (SD)
Oral	33	2.7 (2.2)	11	3.3 (2.8)	0.57
Intravenous	33	0.5 (1.1)	11	0.9 (1.6)	0.34
New bronchopulmonary germ colonization, n (%)
Any germ	33	13 (39)	11	0	0.013
H. Influenza	33	1 (3)	11	0	0.54
S. Aureus	33	3 (9)	11	0	0.29
P. Aeruginosa	33	6 (18)	11	0	0.12
B. Cepacia	33	0 (0)	11	0	1.00
A. Fumigatus	33	3 (9)	11	0	0.32

Both are compared to reference data and expressed as percent predicted values, based on age, gender, and height
FEV₁ forced expiratory volume in one second, FVC forced vital capacity, SD standard deviation
^aMissing data were imputed

ISSN: 1471-2334